CN102292346A - 肥胖的治疗 - Google Patents
肥胖的治疗 Download PDFInfo
- Publication number
- CN102292346A CN102292346A CN2010800051516A CN201080005151A CN102292346A CN 102292346 A CN102292346 A CN 102292346A CN 2010800051516 A CN2010800051516 A CN 2010800051516A CN 201080005151 A CN201080005151 A CN 201080005151A CN 102292346 A CN102292346 A CN 102292346A
- Authority
- CN
- China
- Prior art keywords
- peptide
- residue
- seq
- aminoacid sequence
- asparagines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
活性剂或赋形剂 | 功能 |
SEQ ID NO:3的肽 | 抑制食欲的活性剂 |
包被的柠檬酸 | 蛋白酶抑制剂 |
月桂酰肉碱 | 吸收增强剂 |
非离子聚合物 | 内层包衣 |
Eudragit L30D-55 | 肠溶包衣 |
Claims (45)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20575009P | 2009-01-22 | 2009-01-22 | |
US61/205,750 | 2009-01-22 | ||
PCT/US2010/021872 WO2010085700A2 (en) | 2009-01-22 | 2010-01-22 | Treatment for obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102292346A true CN102292346A (zh) | 2011-12-21 |
CN102292346B CN102292346B (zh) | 2015-12-02 |
Family
ID=42356411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080005151.6A Expired - Fee Related CN102292346B (zh) | 2009-01-22 | 2010-01-22 | 肥胖的治疗 |
Country Status (11)
Country | Link |
---|---|
US (6) | US8076291B2 (zh) |
EP (1) | EP2389388B1 (zh) |
JP (1) | JP5753097B2 (zh) |
KR (1) | KR20110119707A (zh) |
CN (1) | CN102292346B (zh) |
AU (1) | AU2010206614B2 (zh) |
BR (1) | BRPI1006943A2 (zh) |
CA (1) | CA2750035C (zh) |
DK (1) | DK2389388T3 (zh) |
ES (1) | ES2622877T3 (zh) |
WO (1) | WO2010085700A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102965327A (zh) * | 2012-12-12 | 2013-03-13 | 黑龙江大学 | msCT-rhLeptin融合蛋白转基因工程菌株 |
CN102964452A (zh) * | 2012-12-12 | 2013-03-13 | 黑龙江大学 | 用于治骨质疏松症和肥胖的msCT-rhLeptin融合蛋白及编码该融合蛋白的核酸 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1006943A2 (pt) | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
LT3095484T (lt) * | 2011-11-02 | 2018-08-10 | Keybioscience Ag | Kalcitonino mimetikai, skirti ligų ir sutrikimų gydymui |
MX351092B (es) * | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
PL2838914T3 (pl) * | 2012-04-19 | 2017-11-30 | Novo Nordisk A/S | Analogi ludzkiej amyliny |
AR101742A1 (es) | 2014-09-04 | 2017-01-11 | Novo Nordisk As | Agonista del receptor de calcitonina y amilina |
GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
SG10202110874TA (en) | 2016-06-07 | 2021-11-29 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
JP6878615B2 (ja) | 2017-03-23 | 2021-05-26 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. | Shp2阻害剤として有用な新規な複素環式誘導体 |
JP2022504596A (ja) | 2018-10-11 | 2022-01-13 | インターシア セラピューティクス,インコーポレイティド | ヒトアミリンアナログペプチド及び使用方法 |
AR124295A1 (es) | 2020-12-18 | 2023-03-15 | Lilly Co Eli | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
US4764589A (en) | 1987-05-26 | 1988-08-16 | Rorer Pharmaceutical Corporation | [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin |
US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
US5175146A (en) * | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
US5527771A (en) * | 1991-01-10 | 1996-06-18 | Amylin Pharmaceuticals, Inc. | Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions |
US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
US5527790A (en) * | 1991-09-30 | 1996-06-18 | The University Of British Columbia | Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar |
JPH083196A (ja) * | 1994-06-21 | 1996-01-09 | Sanwa Kagaku Kenkyusho Co Ltd | カルシトニン誘導体及びその用途 |
DE726075T1 (de) * | 1995-02-08 | 1996-12-12 | Therapicon Srl | Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
DE69634822T2 (de) | 1995-08-22 | 2006-04-27 | Japan Tobacco Inc. | Amid-verbindungen und ihre anwendung |
DK1005526T3 (da) | 1997-04-16 | 2011-02-07 | Unigene Lab Inc | Direkte ekspression af peptider i kulturmedium |
US6083480A (en) * | 1997-05-01 | 2000-07-04 | Diatide, Inc. | Calcitonin receptor binding reagents |
US6086018A (en) | 1997-12-09 | 2000-07-11 | Mcdonnell Douglas Corporation | Interlocking assembly system for an aircraft cabin |
JP2000290295A (ja) * | 1999-03-31 | 2000-10-17 | Asahi Chem Ind Co Ltd | N−アセチルグルコサミニルカルシトニン |
CN1274830C (zh) * | 2001-12-14 | 2006-09-13 | 中国农业科学院生物技术研究所 | 一种新型鲑鱼降钙素类似物及其在植物油体中表达的方法 |
BRPI0507623A (pt) * | 2004-02-11 | 2007-07-03 | Amylin Pharmaceuticals Inc | peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los |
CN1980954A (zh) * | 2004-02-11 | 2007-06-13 | 安米林药品公司 | 胰岛淀粉样多肽家族肽及其制备和使用方法 |
US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
GB0422644D0 (en) | 2004-10-12 | 2004-11-10 | Novartis Ag | Organic compounds |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
ES2330671T3 (es) * | 2005-03-31 | 2009-12-14 | Amylin Pharmaceuticals, Inc. | Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos. |
EP1907561B1 (en) | 2005-06-24 | 2013-08-28 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
BRPI1006943A2 (pt) | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
-
2010
- 2010-01-22 BR BRPI1006943-7A patent/BRPI1006943A2/pt not_active IP Right Cessation
- 2010-01-22 ES ES10733943.4T patent/ES2622877T3/es active Active
- 2010-01-22 EP EP10733943.4A patent/EP2389388B1/en not_active Not-in-force
- 2010-01-22 US US12/692,502 patent/US8076291B2/en not_active Expired - Fee Related
- 2010-01-22 JP JP2011548156A patent/JP5753097B2/ja not_active Expired - Fee Related
- 2010-01-22 CA CA2750035A patent/CA2750035C/en not_active Expired - Fee Related
- 2010-01-22 CN CN201080005151.6A patent/CN102292346B/zh not_active Expired - Fee Related
- 2010-01-22 WO PCT/US2010/021872 patent/WO2010085700A2/en active Application Filing
- 2010-01-22 AU AU2010206614A patent/AU2010206614B2/en not_active Ceased
- 2010-01-22 KR KR1020117018879A patent/KR20110119707A/ko not_active Application Discontinuation
- 2010-01-22 DK DK10733943.4T patent/DK2389388T3/en active
-
2011
- 2011-11-14 US US13/295,906 patent/US8217139B2/en not_active Expired - Fee Related
- 2011-11-14 US US13/295,936 patent/US8378067B2/en active Active
-
2012
- 2012-07-09 US US13/544,256 patent/US8497347B2/en active Active
-
2013
- 2013-06-28 US US13/930,438 patent/US9394342B2/en active Active
-
2016
- 2016-07-18 US US15/212,432 patent/US9833494B2/en active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102965327A (zh) * | 2012-12-12 | 2013-03-13 | 黑龙江大学 | msCT-rhLeptin融合蛋白转基因工程菌株 |
CN102964452A (zh) * | 2012-12-12 | 2013-03-13 | 黑龙江大学 | 用于治骨质疏松症和肥胖的msCT-rhLeptin融合蛋白及编码该融合蛋白的核酸 |
CN102965327B (zh) * | 2012-12-12 | 2014-06-11 | 黑龙江大学 | msCT-rhLeptin融合蛋白转基因工程菌株 |
CN102964452B (zh) * | 2012-12-12 | 2015-09-09 | 黑龙江大学 | 用于治骨质疏松症和肥胖的msCT-rhLeptin融合蛋白及编码该融合蛋白的核酸 |
Also Published As
Publication number | Publication date |
---|---|
JP5753097B2 (ja) | 2015-07-22 |
CA2750035C (en) | 2018-02-27 |
BRPI1006943A2 (pt) | 2021-06-15 |
US20120142586A1 (en) | 2012-06-07 |
US8217139B2 (en) | 2012-07-10 |
CN102292346B (zh) | 2015-12-02 |
US20120302497A1 (en) | 2012-11-29 |
US20160354434A1 (en) | 2016-12-08 |
AU2010206614B2 (en) | 2015-03-26 |
KR20110119707A (ko) | 2011-11-02 |
JP2012515794A (ja) | 2012-07-12 |
US9394342B2 (en) | 2016-07-19 |
US8497347B2 (en) | 2013-07-30 |
CA2750035A1 (en) | 2010-07-29 |
EP2389388B1 (en) | 2017-03-08 |
US20120149635A1 (en) | 2012-06-14 |
EP2389388A2 (en) | 2011-11-30 |
WO2010085700A3 (en) | 2010-09-23 |
US9833494B2 (en) | 2017-12-05 |
US20140073561A1 (en) | 2014-03-13 |
US8076291B2 (en) | 2011-12-13 |
AU2010206614A1 (en) | 2011-08-04 |
US8378067B2 (en) | 2013-02-19 |
EP2389388A4 (en) | 2013-08-21 |
ES2622877T3 (es) | 2017-07-07 |
DK2389388T3 (en) | 2017-05-01 |
US20100311650A1 (en) | 2010-12-09 |
WO2010085700A2 (en) | 2010-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102292346A (zh) | 肥胖的治疗 | |
DK2344519T3 (en) | C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1) | |
JP5485876B2 (ja) | 代謝疾患の治療における治療剤としての非アシル化グレリン | |
TW201309323A (zh) | 新穎之長效升糖素共軛物及包含其用於肥胖預防與治療之醫藥組成物 | |
JP2016519130A (ja) | 治療ペプチド | |
CN101203531A (zh) | 修饰的pyy(3-36)多肽及它们对进食行为的影响 | |
CA2223611A1 (en) | Appetite regulating compositions | |
NZ255461A (en) | Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity | |
EP4226932A1 (en) | Pharmaceutical composition for preventing or treating periodontal disease or luxated teeth | |
Balasubramaniam et al. | Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine | |
JP5529014B2 (ja) | 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体 | |
RU2811919C1 (ru) | Фармацевтическая композиция для предотвращения или лечения пародонтоза или травматического вывиха зуба | |
JP2001335596A (ja) | 新規ペプチド及びその医薬用途 | |
CA3230915A1 (en) | New peptides as potent and selective gip receptor agonists | |
AU5422596A (en) | Peptides with growth promotion properties | |
MXPA97009880A (en) | Apet regulatory compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANJIAN BIOLOGICAL SCIENCE CO., LTD. Free format text: FORMER OWNER: UGP THERAPEUTICS, INC. Effective date: 20140710 Owner name: UGP THERAPEUTICS, INC. Free format text: FORMER OWNER: UNIGENE LAB INC. Effective date: 20140710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140710 Address after: Swiss Stans Applicant after: KEYBIOSCIENCE AG Address before: Illinois State Applicant before: UGP Therapy Co.,Ltd. Effective date of registration: 20140710 Address after: Illinois State Applicant after: UGP Therapy Co.,Ltd. Address before: New jersey, USA Applicant before: Unigene Laboratories Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151202 Termination date: 20200122 |